Breast Cancer Clinical Trials in Ohio

Showing 321-340 of 636 trials

HydroMARK Post-market Clinical Follow-up Study

NCT04622696

The purpose of this study is to assess the safety and performance of the HydroMARK Breast Biopsy Site Marker manufactured in the Devicor Medical Products, Inc. Tijuana facility.

Breast Cancer

Devicor Medical Products, Inc.730 participantsStarted Feb 2021

Columbus, Ohio, United States • Toledo, Ohio, United States • Morgantown, West Virginia, United States

COMPLETEDPhase 232 miles

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01142401

This randomized phase II trial studies how well fulvestrant works with or without bortezomib in treating patients with estrogen receptor positive breast cancer that has spread to other places in the body and cannot be removed by surgery. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Bortezomib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. It is not yet known whether fulvestrant is more effective with or without bortezomib in treating breast cancer.

Metastatic Breast CarcinomaStage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7+1 more

National Cancer Institute (NCI)118 participantsStarted May 2010

Farmington, Connecticut, United States • New Haven, Connecticut, United States • Weston, Florida, United States +18 more locations

HydroMARK Post-market Clinical Follow-up Study

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Breast Cancer Trials in Other Cities

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Other Conditions in Ohio